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Parasiticidal Effect of Chemotherapy in Alveolar Hydatid Disease: Review of 
Experience with Mebendazole and Albendazole in Alaskan Eskimos 
J. F. Wilson, R. L. Rausch, B. J. McMahon, From the Departments of Surgery and Medicine, Alaska Native Medical 
and P. M. Schantz Center, Anchorage, Alaska; the Department of Comparative Medicine, 
School of Medicine, University of Washington, Seattle, Washington; and 
the Parasitic Disease Division, Centers for Disease Control, 
Atlanta, Georgia 
Evidence that the larval stage of Echinococcus multilocularis n humans is killed by chemother- 
apy is presented in a review of our 17-year experience with treatment of alveolar hydatid disease 
in Alaska. The efficacy of chemotherapy was assessed with use of an in vivo assay of parasite 
viability by means of inoculation of voles, immunohistochemical tests, and histopathologic find- 
ings. Of 14 tests performed for nine patients, 12 in vivo assays (86%) were negative after chemo- 
therapy, while only two (17%) of 12 vole tests for seven untreated patients were negative. Regres- 
sion or arrest of growth of metastatic and primary hepatic lesions, together with their 
partial-to-complete calcification and prolonged survival times has been observed among patients 
treated with the benzimidazole compounds. For six who received appropriate chemotherapy, 
treatment has been discontinued for an average of 4.6 years (range, 3-7 years) without an in- 
crease in lesion size or other evidence of reactivation. 
Alveolar hydatid disease (AHD), caused by the larval 
stage of the cestode Echinococcus multilocularis, is a serious 
health problem among Eskimos in northwestern Alaska, as 
well as in various populations in Eurasia. E. multilocularis is 
indigenous to the arctic tundra, where arctic foxes and small 
rodents (voles and lemmings) serve as the final and interme- 
diate hosts. The disease has an extensive distribution in the 
northern hemisphere, but in North America most autochtho- 
nous cases of AHD have been diagnosed in Eskimos in north- 
western Alaska. Although good results have been achieved 
in cases of resectable lesions, before 1986 8 1% of patients in 
Alaska had nonresectable lesions at the time of diagnosis. In 
a report of 1,41 1 operations for AHD performed in the Com- 
monwealth of Independent States, Zhuravlev [1] also found 
the resectability rate to be low ( 18%). These findings clearly 
reflect the need for an alternate method of treatment of 
AHD. 
E. mnultilocularis was first identified in the Western Hemi- 
sphere on St. Lawrence Island, Alaska, in 1951 [2] (a few 
earlier cases of AHD were diagnosed retrospectively). Thus 
far 70 autochthonous cases of AHD have been diagnosed in 
North America, and all but two have occurred among Eski- 
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mos from St. Lawrence Island and from a hyperendemic area 
on the mainland of northwestern Alaska. 
Clinical evaluations of patients, surgeries, and autopsies 
were conducted at the Alaska Native Medical Center, which, 
since its establishment in May 1953 in Anchorage, has been 
the location of the patient-related work concerning AHD. 
This center is a facility of the U.S. Public Health Service and 
is the referring institution for a broad-based health delivery 
system serving the needs of all indigenous peoples in Alaska. 
The organization includes village clinics staffed by trained 
Native American health aides and supported by five small, 
regional field hospitals. Biological and epidemiological in- 
vestigations concerning E. multilocularis were initiated at the 
Arctic Health Research Center of the U.S. Public Health 
Service in 1950 and later undertaken also at the Arctic Inves- 
tigations Program of the Centers for Disease Control in An- 
chorage. Consequently, the investigations concerning E. 
multilocularis and AHD have continued without interrup- 
tion for -40 years, and some of the same personnel have 
been involved for all or most of that period. Aside from basic 
biological studies, major aspects of this study have included 
clinical chemotherapy trials and the development of screen- 
ing and preventive programs [3]. 
During the early years of this experience, most of the pa- 
tients with AHD were admitted to the hospital with an ab- 
dominal mass or symptoms related to the primary hepatic 
lesion. For some patients the initial diagnosis was made on 
the basis of a positive screening serology with use of the indi- 
rect hemagglutination method. In 1985 an improved serolog- 
ical technique with use of a specific antigen of E. multilocu- 
laris was introduced [4, 5]; and in 1988 field trials were 
initiated in which a portable ultrasonography (US) unit was 
used for screening in four high-risk villages, which resulted in 
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the diagnosis of four active cases at an early stage of develop- 
ment. Another result of the improved method of screening 
was the identification of patients with a number of small, 
calcified hepatic lesions that on further study were found to 
represent lesions in which the larval cestode had died [6]. 
Five of these lesions were resected to confirm the diagnosis 
and to permit testing for viability. Thus far, 26 such cases 
have been identified and the patients received a clinical diag- 
nosis of inactive AHD; in 12 cases serologies were positive 
and in 14 the diagnosis was based primarily on the results of 
computed tomography (CT) or US findings. All such inac- 
tive cases are still under investigation and will not be consid- 
ered further here. The 44 locally acquired cases of active 
AHD diagnosed in North America form the basis for this 
review. 
After publication of the report of Heath and Chevis [7], 
widespread interest developed in the use of benzimidazole 
compounds for the treatment of hydatid disease. Clinical 
trials of both mebendazole and albendazole have been con- 
ducted; however, the results have been inconsistent. Some 
authors have reported a poor outcome with these drugs in the 
treatment of cystic hydatid disease [8-1 1], while others have 
obtained more optimistic results with regard to the treatment 
of this condition or AHD [ 12-25]. The purpose of this paper 
is to review in detail our 17-year experience with chemother- 
apy for AHD in Alaska and to present the data that have led 
us to conclude that E. multilocularis can be eradicated by 
treatment with compounds of the benzimidazole group. 
Methods 
The records of all 44 patients with active AHD were re- 
viewed. Tissues were obtained from 14 patients on 26 occa- 
sions for in vivo assays for viability. Chemotherapy has been 
offered to all patients since 1974 (mebendazole through 
1984 and albendazole since 1985). Patients scheduled for 
surgery usually received two or three 28-day courses of al- 
bendazole before resection or biopsy of tissues that were to 
be tested for viability was performed. After a diagnosis of 
AHD was made and clinical and laboratory data were re- 
corded, chemotherapy was initiated as follows: patients re- 
ceived 40 mg/(kg * d) of mebendazole (microcrystalline form 
[Vermox], Janssen, Piscataway, NJ) in three doses with fatty 
meals [12-14, 26]. Albendazole (Zentel), supplied as 200- 
mg tablets by Smith Kline & French Laboratories (Philadel- 
phia), was used with the approval of the U.S. Food and Drug 
Administration after informed consent was obtained. An 
oral dose of 400 mg was taken b.i.d. with meals according to 
a protocol in which 28-day courses of therapy are alternated 
with 14-day drug-free intervals [27] (for convenience, such a 
course, although consisting of 28 days of therapy given dur- 
ing a 42-day period, will be referred to as 1 month of chemo- 
therapy). 
The eficacy of chemotherapy for AHD was assessed by a 
combination of methods in addition to clinical findings. An 
in vivo test for viability of the larval cestode has been based 
on the intraperitoneal inoculation of membranes from pa- 
tients into red-backed voles (Clethrionomys rutilus [Roden- 
tia: Arvicolidae]). More recently, equally good results have 
been obtained with northern voles (Microtus oeconomous) 
and Mongolian gerbils (Meriones unguiculatus) (the red- 
backed and northern voles are natural intermediate hosts of 
E. multilocularis on St. Lawrence Island and in major regions 
of Europe and Asia endemic for AHD). We examined inocu- 
lated rodents 3-4 months postinoculation to determine re- 
sults. The proliferation of vesicles confirmed that the larval 
cestode was viable. 
Tissues for bioassay were obtained by means of surgical or 
needle biopsy on 14 occasions from nine individuals who 
had received at least 2 years of therapy with mebendazole or 
2 months of therapy with albendazole (table 1). These param- 
eters were based empirically on results of bioassays per- 
formed before 1985 (for all patients treated for >24 months, 
with one exception, the results were negative) [26]. Since 
vesicles of the larval cestode in host tissue remain infective 
for > 1 week when stored under refrigeration, vesicles ob- 
tained at autopsy 2-3 days postmortem were suitable for 
testing. Untreated patients for whom in vivo tests were per- 
formed served as historical controls. Patients who received 
insufficient chemotherapy, as defined above, are for present 
purposes described as undertreated. Twelve tests were per- 
formed for 10 untreated or undertreated individuals. 
The reliability of the in vivo test depends on whether an 
adequate quantity of membranes from the patient's tissues 
has been obtained. Material obtained by needle biopsy is the 
least reliable, since few, if any, membranes may be present. 
In contrast to tissues of E. multilocularis that are used for 
maintaining isolates in the laboratory, also transferred by 
intraperitoneal inoculation, those obtained from patients are 
difficult to quantify for in vivo tests. Fully developed larval 
cestodes from rodents consist of a dense aggregation of mi- 
crocysts with abundant protoscolices and little or no host 
tissue. Consequently, uniform 0. l-g samples are readily ob- 
tainable. In humans, however, sterile vesicles (lacking proto- 
scolices) that are usually of small size are dispersed in a dense 
matrix of collagen that has replaced hepatic tissue. In collect- 
ing material for inoculation, slices of the lesion are examined 
for cavities containing membranes (figure 1), which are 
translucent and often folded [28]. The membranes are re- 
moved by means of fine-pointed forceps and placed in saline, 
after which aliquots are prepared for inoculation into the 
rodents (three rodents were routinely inoculated, unless the 
quantity of membranes was insufficient). 
When normally developed larval E. multilocularis consists 
of great numbers of closely apposed, interconnected vesicles, 
each made up of an external nonviable layer, the laminated 
membrane, and an internal layer of germinal tissue from 
which brood capsules and protoscolices arise. When found 
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Table 1. Efficacy of chemotherapy determined by in vivo assay of parasite viability in voles for 
untreated and treated patients with alveolar hydatid disease. 
Results of assay 
(no. of voles) 
Date No. of No. of 
Patient Source of tissue months of No negative 
Treatment no.* tissue obtained chemotherapy Growth growth tests (%) 
Untreated 26 Resection 10/71 0 2 1 
30 Resection 8/73 0 2 1 
4 Surgical biopsy 11/74 0 1 2 
wt Resection 10/77 0 3 2 
35 Surgical biopsy 11/80 0 0 2 
38 Resection 6/84 0 2 0 
51 Surgical biopsy 5/87 0 2 0 
1 (14) 
Undertreated 
Mebendazole (<2 y) 
5 Needle biopsy 2/77 6 1 0 
5 Surgical biopsy 2/77 6 1 1 
34 Surgical biopsy 2/82 15 1 3 
1 (10) 
Albendazole (<2 mo) 
42 Surgical biopsy 10/85 1 0 2 
42 Surgical biopsy 2/88 1 1 1 
2 (17) 
Treated 
Mebendazole (>2 y) 
4 Needle biopsy 11/78 48 1 1 
1 Surgical biopsy 12/78 37 0 1 
I Surgical biopsy 2/80 62 0 3 
34 Surgical biopsy 11/82 24 0 1 
1 Autopsy 4/84 108 0 2 
34 Autopsy 10/84 37 0 2 
3 Autopsy 3/85 123 0 3 
30 Autopsy 9/85 42 0 3 
4 Surgical biopsy 11/86 143 0 2 
35 Surgical biopsy -/86 72 0 2 
35 Surgical biopsy 3/90 74 0 2 
10 (91) 
Albendazole (>2 mo) 
39 Surgical biopsy 5/85 2 0 2 
42 Surgical biopsy 3/90 9 1 5 
60 Surgical biopsy 5/91 3 1 2 
11 (79) 
NOTE. For seven untreated patients, seven tests were performed; for nine undertreated patients who received 
mebendazole, 10 tests were performed; for 10 undertreated patients who received albendazole, 12 tests were 
performed; for six treated patients who received mebendazole, 11 tests were performed; and for nine treated 
patients who received albendazole, 14 tests were performed. 
* Patient no. corresponds with that in text [13]. 
t Patient from Wisconsin. 
in humans, however, the organism's germinal layer is very 
thin and usually not discernible by light microscopy. In ac- 
tive lesions of AHD, all germinal tissue in the peripheral 
zone of proliferation is presumably viable; it is from that 
zone that surgical and needle biopsy specimens are obtained. 
Vesicles in such tissues consist of laminated membrane, pre- 
sumably with a thin layer of germinal tissue which, when 
inoculated into rodents, undergoes proliferation and ulti- 
mately produces protoscolices. We have routinely inocu- 
lated 10-1 5 small vesicles, judged from experience to be ade- 
quate for producing vesicles in an individual rodent (figure 
2). The minimal number of cells required for proliferation is 
unknown, but Furuya [29] determined that growth occurred 
when 107 undifferentiated (germinal) cells from tissue cul- 
tures were inoculated into cotton rats (Sigmodon hispidus). 
The germinal membrane in paraffin sections is stained by 
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Figure 1. Cut surface of a typical lesion of AHD in the liver (case 
60). Arrows indicate cavities filled by membranes of the larval E. 
multilocularis. The scale bar has a value of 5 mm. 
means of the avidin-biotin immunohistochemical (ABC) 
method [30]. With this technique active lesions can be distin- 
guished from those in which the larval cestode has died spon- 
taneously, but it appears to be of limited value in assessing 
the effect of long-term mebendazole therapy. In such cases, 
positive staining has been observed for scattered vesicles 
which, as indicated by other evidence, were nonviable [30]. 
It is often difficult to determine whether the larval cestode 
in lesions is dead or alive when it is assessed by means of the 
usual histopathologic methods. The laminated membrane 
may persist even in totally calcified lesions in which the lar- 
val cestode was evidently nonviable for 10-30 years [6]. 
Nonetheless, such membranes in decalcified tissues stain 
strongly when the periodic acid-Schiff method is used and 
often do not differ in staining characteristics from mem- 
branes taken from active lesions. The presence of the lami- 
nated membrane in nonactive lesions may account for a per- 
sistent antibody response. Since protoscolices are very rarely 
produced in humans (they were found in a metastatic lesion 
in the brain in only one of our cases), viability cannot be 
established on the basis of observation of flame cells or by 
less reliable methods of staining [311. Signs of degenerative 
changes in laminated membranes and the characteristics of 
the cellular response are useful in distinguishing nonviable 
vesicles. 
Clinical Experience 
The effect that chemotherapy has had on the clinical 
course of the disease was also evaluated. Among 31 patients 
for whom the diagnosis was made before 1974, six were 
cured with surgical resection and two underwent incomplete 
resections. Twenty-three patients with nonresectable disease 
initially received no chemotherapy. Early in this experience 
five cases were excluded from analysis because clinical data 
were insufficient for assessment (data on these five cases 
were included only with regard to survival). Two cases in 
which incomplete resections were performed and one recent 
case (case 42 in which severe undertreatment occurred be- 
cause of noncompliance with therapy) are added to the re- 
maining 18 untreated cases to give a total of 21 patients who 
had active untreated or undertreated lesions and who were 
observed over time. They serve as the historical controls to 
be compared with 13 patients who received chemotherapy 
(table 2). (Eleven active cases were diagnosed after 1974 
when chemotherapy trials were initiated; of these, data from 
three are not included because the patients died of causes 
unrelated to AHD before they had received 2 years of me- 
bendazole therapy.) Five patients in the untreated group 
eventually received chemotherapy (cases 1, 2, 3, 30, and 42), 
and data from these cases appear in both the treated and 
untreated categories, resulting in analysis of 34 cases. 
In this study the sizes of untreated hepatic lesions were 
largely determined during physical examination by measur- 
ing the palpable liver edge or hepatic mass below the costal 
margin. Before 1975 the only means for monitoring the prog- 
ress of lesions was by physical examination, and thus it was 
customary for the physician to conduct thorough examina- 
tions and to record results at the time of each clinic visit. 
Most of the examinations were performed by one of the au- 
thors over the period of 1961 to the present. Data from physi- 
cal examinations represent, in nearly all cases, the average 
measurements derived from several cases. Lesions of treated 
cases were more precisely monitored by CT and US, imaging 
techniques not previously available. Overall progression was 
assessed by measuring the change in lesion size as deter- 
mined by physical examination or imaging methods or on 
the basis of extension of disease, the development of end- 
stage disease or metastases, and other clinical criteria. 
a~~~ 
Figure 2. Appearance of vesicles of E. multilocularis taken from 
tissue shown in figure 1. The quantity shown was sufficient for 
inoculating three voles and inducing proliferation. Each space has a 
value of I mm. 
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Table 2. Summary of clinical data on patients with untreated and treated alveolar hydatid disease. 
Status of lesion over time 
Progression 
Case Summary 
no./age Years Initial Final of 
(y) Date observed size size* Growtht Extensiont Metastases ESD progression Clinical findings 
Untreated and 
undertreated 
patients 
1/340 12/66 8 5 12 + - Lung, + OP Hepatic abscess (20 X 25 cm); 
mediastinum, then mediastinal and 
lymph nodes pulmonary mets and ESD 
2/67? 12/69 5 0 1.4"1 + - - + OP Rapidly enlarging widespread 
pulmonary mets; ESD 
3/56? 6/71 4 4 13 + + Brain, retina + SP Lesion (26 cm) with extension 
through diaphragm; ESD, 
1969 
30/65? 3/73 7 0 5 X 8.4 + - - - OP Lesion (2 cm) "resected for 
cure"; increasing serum 
antibody titers and 
diagnosis of a recurrent 5 X 
8-cm lesion on CT, 10/80 
42/20? 4/85 2.7 7.7 9.8 + - - - OP Lesion (8 cm) inadequately 
treated, 1985-1988; 
noncompliance with 
chemotherapy and low 
serum level of ALBZ led to 
reactivation 
23/52# 1/47 11 2 10 + + - + SP Duodenal mass and mets to 
liver on surgery, 1947; 
massive hepatic abscess; 
marsupialization 
10/30# 1/50 2.5 ND ND + - Brain + SP Mets to brain; craniotomy, 
11/50; protoscolices found 
in microcysts of brain; died 
25/30# 1950 13 15 ND + + - + SP Lesion (15 cm) partially 
excised, 1950; pain and 
jaundice, 1954; hepatocolic 
fistula and fatal 
hemorrhage, 1963 
24/54# 7/57 1 10 + - Brain + SP Hepatomegaly, abdominal 
mass (10 cm); CNS 
symptoms; fatal brain mets 
17/74* 5/58 0.1 7 X 10 + + Lung + SP Jaundice; abdominal mass 
diagnosed as cancer; 
massive ESD with extension 
into duodenum; mets to 
lung and fatal hemorrhage, 
1963 
19/53? 2/59 13 0 8 + + - + SP Large hepatic mass with 
extension into IVC; 
anasarca; death 13 y after 
diagnosis 
33/22' 2/60 3 0 14 X 16** + + - + OP Jaundice; stony-hard mass (8 
X< 12 cm) of left lobe 
resected; recurrence within 
3 y with massive lesion (14 
X 16 cm) extending through 
diaphragm; biliary 
obstruction; death 
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Table 2. (Continued) 
Status of lesion over time 
Progression 
Case Summary 
no./age Years Initial Final of 
(y) Date observed size size* GrowthW Extensiont Metastases ESD progression Clinical findings 
11/65' 1960 4.5 6 17 + + - + SP Diagnosis by serosurvey; 
progression to ESD; liver 
enlarged (from 6 cm to 17 
cm below costal margin); 
IVC obstruction; anasarca 
and death 
14/51' 11/60 10.4 3 8 + - Brain + SP Diagnosis by serology; 
increasing liver size for 11 
y; fatal brain mets 
6/62 8.6 10 0n - + - - R Spontaneous drainage of large 
abscess by fistula to skin 
(persisted 8 y); died of other 
causes 
12/53? 8/62 0.2 10 X 7 + + - + SP Jaundice (3 mo); surgical 
exploration for ESD; central 
lesion (10 X 7 cm) with 
obstruction of IVC 
15/28? 10/67 0.1 ND ND + - Brain + SP Seizures, craniotomy for 
"brain abscess"; died I mo 
later 
9/62? 12/67 7 0 8 + - - - OP Liver scan (negative), 1967; 
repeated, 1972 (multiple 
hepatic lesions); died with 
advanced AHD 
7/53tt 12/63 1 1 3 13 + - - + SP Nodular liver on physical 
examination; increasing size 
of liver; died of pneumonia 
8/82? 1970 5 2 10 + - - + SP Diagnosis by serosurvey; 
increasing liver size; died of 
ESD; lesion ( 16 cm) at 
autopsy 
6/74? 2/71 6 4 12 + + - + SP Diagnosis by serology; 
progressed to ESD; IVC 
obstructed; anasarca 
Treated 
(mebendazole) 
1/42" 12/74 17.3 21 8t - - - - OR Regression of substernal mets 
(26-8 mm); clinically 
improved for 10 y; died of 
late complications of AHD 
2/62111" 1/75 21.9 1.41 1.41 OR Rapid growth of pulmonary 
mets arrested by MBZ ( 1/75 
to 3/86); 27 of 30 
pulmonary nodules and 
primary hepatic lesions 
totally calcified, appear 
inactive on CT (5/89); 
clinically well 
3/61"? 1/75 13.7 26 - - Brain, retina - R See table 3 
30/72""l 10/80 12.1 5 X 8.4 2 X 4** - - - - OR See table 3 
4/4311112/74 16.9 20 10.5 - - - - OR See table 3 
5/651lll4/76 15.5 7 X 10 7 X 10 - - - - U Diagnosed by serology; vole 
assay positive after 
chemotherapy (5 mo); no 
increase in lesion size for 
8.5 y; therapy with MBZ 
(8/78 to 2/85); strongly 
positive serology now 
negative for 5 y 
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Table 2. (Continued) 
Status of lesion over time 
Progression 
Case Summary 
no./age Years Initial Final of 
(y) Date observed size size* Growtht Extensiont Metastases ESD progression Clinical findings 
34/50" 11/80 3.9 7 X 10 9.7 - - - - OR Therapy with MBZ (11/80 to 
12/83); growth of two 
central lesions arrested for 
4 y; obstruction of common 
bile duct; external tube 
drainage for 10 mo; biliary 
cirrhosis and portal 
hypertension; died 
35/56tt 10/80 9.5 5.4 X 6.6 4.7 X 6 - - - OR See table 3 
Treated 
(albendazole) 
42/201""1 4/85 6.6 9.8 11 + - - - P See text 
39/511l11 2/85 6.7 4.3 S - - _ - OR Diagnosis by serosurvey; after 
therapy with ALBZ (2 mo) 
lesion resected; in vivo 
viability assay negative; 
postoperative serologies 
negative for 6.5 y 
5 1/671""1 2/87 4.7 3.4 X 4.5 3.5 X 3.9 - - - - U Lesion (4 cm) found 
incidentally on CT, 2/87; 
open biopsy specimen gave 
positive vole viability 
results; therapy with ALBZ 
(3.7 mo); severe dermatitis; 
ALBZ discontinued (see 
table 4) 
53/331111 6/88 3.3 2 X 4 1.5 X 3.2 - - - - OR Lesion (2 X 4 cm, mixed 
density) found on US; 
therapy with ALBZ (7 mo) 
tolerated; resection offered, 
declined (see table 4) 
60/531""1 2/91 0.7 3 X 3 S OR Suspicious finding on 
screening US, 6/88; US 
negative when repeated 6/ 
89; serum antibody titers 
elevated, lesion (3 cm, 
mixed density) found on 
CT; ALBZ therapy for 3 
mo; lesion resected 5/91; 
weakly positive results in 
one of three voles; 12 mo 
of therapy with ALBZ 
scheduled 
NOTE. ESD = end-stage disease; + = occurred; - = did not occur; OP = objective evidence of progression; mets = metastases; SP = severe progression; 
CT = computed tomography; ALBZ = albendazole; ND = not determined; IVC = inferior vena cava; R = regression; AHD = alveolar hydatid disease; OR = 
objective evidence of regression or negative in vivo assay; MBZ = mebendazole; U = unchanged; P = progression; S = no evidence of recurrence; and US = 
ultrasonography. 
* Lesion size or hepatomegaly determined on physical examination, CT, or roentgenography. 
tIf patient died of brain metastasis or overwhelming AHD, growth is presumed. 
$Obstruction of vena cava or portal vein or fistula to the skin, bowel, or pleura. 
' Patient eventually treated. 
"1Pulmonary metastases (average of five nodules). 
* Death directly related to AHD. 
** Size of lesion measured at autopsy. 
tt Died of unrelated causes. 
t$ Change in size due to drainage of abscess. 
" Died of late complications of AHD; viability assay negative. 
Alive. 
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End-stage disease was defined as that involving a massive 
lesion (diameter, > 15 cm or liver edge > 11 cm below the 
costal margin), and extension of disease was defined as that 
causing obstruction of the inferior vena cava, major hepatic 
bile ducts, or portal vein or the development of fistulae or 
distant metastases [26]. Progression of disease is severe and 
unequivocal: if a patient had end-stage disease before the 
start of chemotherapy and died of late complications of 
AHD, the case was not described as showing severe progres- 
sion or as developing end-stage disease while receiving che- 
motherapy. 
Results 
Long-term mebendazole therapy. Eight patients were 
treated with mebendazole for >2 years. Of these, tissues were 
obtained for viability studies from six. A needle biopsy speci- 
men from one patient (case 4) was positive in 1978, 48 
months after therapy was initiated. Tissues were evaluated 
on 10 other occasions from these six patients. Five specimens 
were obtained at autopsy and five during surgical explora- 
tion. The autopsy findings and in vivo results for two of the 
patients have been previously reported [26]. Table 3 presents 
a summary of data for the remaining four patients (see also 
figures 3 and 4). 
Short-term albendazole therapy. Five patients were 
treated with albendazole. Two lesions measuring 4.3 cm and 
3 cm were resected after 58 and 84 days of therapy, respec- 
tively. The in vivo assay of resected tissues was negative for 
the first patient. For the second patient, whose case was re- 
cently diagnosed (case 60), proliferation of the larval cestode 
was observed in one of three voles that were injected. How- 
ever, the extent of proliferation was very limited-the weight 
of the metacestode tissue was <0.1 g, as compared with the 
usual weight of 5-15 g when untreated membranes are in- 
jected. These findings suggest reduced viability of the larval 
cestode, with growth from only one of the many microcysts 
injected. Two patients with 4.5- and 4-cm lesions were 
treated with only albendazole for 3.75 months and 7 
months, respectively. No increase in lesion size has been ob- 
served with CT during 4.7 and 3.3 years of follow-up. 
The fifth patient (case 42) was a 20-year-old woman who 
had an 8-cm nonresectable lesion and who was treated for 10 
months with albendazole (400 mg b.i.d.) from June 1985 to 
July 1986 [27]. Although the initial in vivo test performed 
after 3 months of therapy with albendazole was negative, the 
case was complicated by both noncompliance and low serum 
albendazole levels of 3 10 ng/mL. She had received no more 
than 1.5 months of appropriate therapy when reactivation 
with growth of the lesion to 10 cm occurred. A second series 
of treatments for 9 months (600 mg b.i.d.) arrested growth 
for 16 months, and peak serum albendazole levels of 1,320 
and 2,120 ng/mL were attained. However, the lesion then 
increased in size to 11 cm, and results of an in vivo assay 
were positive. A third series of treatments with albendazole 
for 9 months was started in February 1990, followed by long- 
term mebendazole therapy. The size of the lesion has been 
stable for 21 months and the patient remains asymptomatic, 
but the long-term prognosis is not clear. Although we believe 
that this patient has been taking her drugs as directed since 
1988, she, very unlike the other patients, has been quite 
unreliable in many ways. In addition, other factors such as 
possible drug resistance or inadequate host immunity must 
be considered as contributing to this delayed treatment fail- 
ure. This is the only case, in our experience, in which the 
larval cestode grew during administration of chemotherapy. 
While it is too early to fully assess this case, we will consider 
it at this time as one in which inappropriate therapy was 
administered. 
Vole-inoculation studies. Data from our experience with 
the vole-inoculation method for assessing the viability of the 
larval cestode of E. multilocularis are presented in table 1. 
Among 12 viability assays of tissue from 10 untreated or 
undertreated patients, 10 (83%) were positive, while only 
two ( 17%) were negative. Of nine treated patients, an assay 
performed in 1978 of a needle biopsy specimen from one 
who had received 48 months of mebendazole therapy was 
positive. Since that time, 11 of 13 consecutive in vivo tests 
for nine treated patients failed to show growth of the larval 
cestode (79% negative). Ten of these negative tests involved 
specimens from patients who had received >2 years of me- 
bendazole therapy, and one involved specimens from the 
patients who had received 2 months of preoperative albenda- 
zole therapy. 
Untreated vs. treated cases. The clinical course of the 29 
study cases is summarized in table 2. Twenty of these were 
diagnosed before 1974, when mebendazole was introduced. 
Four cases were diagnosed by serological screening, while 16 
patients presented with a mass or symptoms. Among 21 un- 
treated patients, increasing severity of hepatomegaly or le- 
sion size, as determined by physical examination, CT, or di- 
rect measurement, was demonstrated in each of the 14 
patients that could be assessed (figure 5). Seven patients 
were excluded: six in whom the size of the lesion could not 
be determined and one (case 16) in whom a large abscess 
drained spontaneously, resulting in a decrease in the degree 
of hepatomegaly. In two cases the disease recurred after per- 
formance of what were believed to have been complete surgi- 
cal resections. The recurrent lesions presumably arose from 
microscopic, residual material that was not discernible at the 
time of surgery; the size of the lesions was considered to be 
zero immediately after surgery. These lesions progressed in 
size to reach diameters of 14 cm and 8 cm within 3 and 7 
years, respectively (cases 33 and 30). 
Drainage procedures or surgical intervention resulted in 
marked reduction in the size of the hepatic abscess in three 
cases (cases 1, 3, and 4). However, these changes were unre- 
lated to the effect of chemotherapy and have been excluded 
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Table 3. Clinical findings and evidence of nonviability of E. multilocularis for patients receiving 
mebendazole therapy. 
Case 
no. Clinical findings Pathological findings Evidence of nonviability 
3 End-stage disease at diagnosis (1971); Extensive AHD of right Negative vole (X 3) and 
hepatic abscess (7-8 L, 18 X 25 lobe of liver and RLL ABC test results; weak 
cm); marked clinical improvement of lung at autopsy; PAS staining; extensive 
with MBZ therapy, 1975-1985; brain met (2.5 cm) necrosis of brain lesion; 
pyogenic infection of hepatic and subretinal met degenerative changes in 
abscess (1977) requiring external (10 mm); vesicles of retinal met 
drainage for 2 y; retinal metastasis E. multilocularis 
(3.25 mm) diagnosed (1980); abundant; 
seizure (1984) led to diagnosis of a inoculation of three 
brain met; led active life until 1/85; voles 
hospitalized, died of sepsis and 
renal failure 
4 Diagnosis by positive serology and Considerable necrosis Negative vole test results (X 
enlarged liver; 12 X 20-cm central of tissue around 2); decrease in lesion size 
lesion treated with MBZ (12/74 laminated without drainage and loss 
to 4/87); abscess decreased from membranes; large of matrix; no recurrence 
20 cm to 10 cm without drainage; proportion of vesicles 4.5 y after MBZ therapy 
biliary obstruction requiring not taking up PAS discontinued 
choledochoduodenostomy and stain; great majority 
partial resection (11 /86) (wall of of membranes gave 
lesion was thin, fibrotic with no negative ABC test 
matrix); biliary stent requires results with rare 
changing every 2-4 mo; patient scattered membranes 
remains active and asymptomatic positive 
17 y after diagnosis 
30 Lesion (12 cm) "resected for cure" Metastatic cancer and Very weak PAS stain uptake, 
(1973); increasing serum antibody E. multilocularis negative ABC and vole 
titers led to diagnosis of a recurrent lesion (2 X 2 X 4 cm) test results (X 3); decrease 
lesion (5 X 8 cm); MBZ therapy on autopsy in lesion size (10/80 to 
42 mo (discontinued 1/85); died of 9/85, from 5 X 8 cm to 2 
cancer of breast, 9/85 X 4 cm) 
35 Positive serology; CT revealed a 6.5- Gelatin-like and friable Degenerative changes in 
cm central hepatic lesion (10/80); laminated laminated membranes, 
MBZ therapy (10/80 to 12/86); membranes in negative vole test results 
biliary stricture required internal autopsy tissue of surgical and autopsy 
drainage with stent (11/86 and 12/ tissues (1990) 
86); maintained active life and full 
employment, then died of 
cerebrovascular accident (4/90) 
NOTE. MBZ = mebendazole; met = metastasis; AHD = alveolar hydatid disease; RLL = right lower lobe; 
ABC = avidin-biotin immunohistochemical test; PAS = periodic acid-Schiff; CT = computed tomography. 
from assessment of change in lesion size. In nine treated 
cases the size of the hepatic lesion has been assessed over 
time (figure 6), and in three cases metastatic lesions have 
been monitored by roentgenography, CT, or US (figure 7). 
The arrest of growth following institution of chemotherapy is 
well illustrated in cases 1 and 2. The continued growth of the 
retinal metastasis in case 3 is possibly explained by poor pen- 
etration of mebendazole through the blood-retina barrier. 
Viability tests of membranes from other lesions in this case 
were negative. Among the 13 treated patients, eight are liv- 
ing. The lesions in two were resected (cases 39 and 60), and 
in another (case 42) the status of the lesion is uncertain. In 
the remaining five, chemotherapy has been discontinued for 
an average of 4.8 years (range, 3-7 years) without evidence 
of any increase in lesion size on semiannual or annual CT 
and US. 
Extension of the disease into adjacent structures was ob- 
served in 10 of 21 untreated cases (48%) and consisted of 
penetration of the diaphragm, formation of a fistula to the 
skin or bowel, or blockage of the inferior vena cava. No ex- 
tension of disease was observed in any of our cases after che- 
motherapy was started. Distant metastases were observed in 
eight of the 29 cases summarized in table 2 and in one pa- 
tient not in the study group. Among untreated patients, four 
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Figure 3. Left, PA chest roentgenogram taken in 1971 of a 58-year old Eskimo man with a massive hepatic lesion after 3,600 mL of fluid 
was aspirated from the lesion and air was injected. Note air-fluid level and elevated diaphragm. Right, flat plate of abdomen after instilling 
contrast medium (abscess measured 25 X 18 X 17 cm). (Reprinted with permission from 1 12]). 
developed symptomatic brain metastases and survived, on 
average, only 0.9 years (range, 1-12 months) after diagnosis; 
for two patients incidental autopsy findings of pulmonary or 
pulmonary and brain metastases were noted. Three patients 
with metastases received chemotherapy and survived an 
average of 17.3 years after diagnosis. In cases I and 2 there 
was objective evidence of regression of widespread metas- 
tases after mebendazole therapy was started (figure 6). In 
case 3 brain and retinal metastases were discovered during 
the period of chemotherapy. However, it is not clear when 
these metastases actually developed. The brain metastasis in 
this case behaved very differently from those of untreated 
patients. No growth was apparent during the year after diag- 
nosis was made by CT, and it did not cause further symptoms 
or contribute to the patient's death. Tissues from metastases 
in cases I and 3 were not submitted for vole inoculation, but 
results of periodic acid-Schiff staining of histologic sections 
and ABC tests were consistent with severely damaged or 
nonviable larval cestodes. Growth in the retinal lesion, how- 
ever, suggests at least that the metastasis was active. 
In untreated cases objective evidence of severe progression 
was observed by roentgenography, CT, or US in six (43%) of 
i"..I3,1su<.'..:.. ............7 
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Figure 4. Left Surgical specimen from internal drainage and unroofing procedure in 1986 after a 43-year-old man presented with a 20 X 
12 X 12-cm nonresectable hepatic lesion in 1974, for which he received mebendazole (3 g daily for 12 years [case 4]). The thin (2-3 mm) 
fibrotic wall of the abscess is held in the forceps. Right, the absence of residual matrix contrasts with the characteristic thick matrix of an 
untreated lesion (autopsy specimen, case 14). 
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Figure 5. Increase in lesion size or hepatomegaly over time in 
untreated or undertreated alveolar hydatid disease. 
14 patients who could be assessed, and the infection ad- 
vanced to end-stage disease in 8 1% (1 7 of 2 1 cases). Consider- 
ing all parameters, severe progression was confirmed in 95% 
of untreated cases. On the basis of the same criteria, none of 
the 13 treated cases showed severe progression. There was 
objective evidence of a favorable response in 10 patients 
(77%) as indicated by regression in lesion size in five patients 
and negative in vivo viability assay for five. On the basis of 
each of these parameters, striking differences are observed 
between treated cases and the untreated controls. 
Su3rvival. In assessing the clinical efect of chemotherapy, 
we had an early favorable impression that survival time was 
extended through its use [13, 14, 26]. Among 21 patients 
who were never treated, the average survival time was 5.3 
years postdiagnosis, and all of those patients have died. 
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Figure 6. Size of the larval E. 7inultilocularis (EM) lesion as deter- 
mined by roentgenography or CT over time in treated alveolar hy- 
datid disease. Note chemotherapy has been discontinued in each 
case except case 42. 
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Figure 7. The effect of mebendazole therapy on the size of meta- 
static lesions of alveolar hydatid disease. The reduction in the size 
of the substernal metastasis of case 1 and the arrest of growth of the 
rapidly enlarging pulmonary metastases in case 2 are attributed to 
mebendazole therapy. AP = anteroposterior. 
Among eight treated patients for whom AHD was diagnosed 
before 1981, survival time now averages 13.6 years (figure 
8). Three patients who had advanced disease when chemo- 
therapy was started are living, with survival time now averag- 
ing 1 8 years. Survival after the onset of end-stage disease was 
0.6 years in the untreated cases and 15.7 years among pa- 
tients in the treated group (figure 9). Because diagnosis has 
been made recently for most patients and their disease was 
identified at an earlier stage when the lesion was smaller, so 
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Figure 8. Comparative survival rates for 33 patients with alveo- 
lar hydatid disease. All untreated patients have died (average sur- 
vival time, 5.3 years). The average survival time for eight treated 
patients who received the diagnosis before 198 1 is 13.6 years and 
three of these are alive. 
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Figure 9. Survival after the onset of end-stage alveolar hydatid 
disease. Nine untreated patients survived only 0.6 years after onset 
of end-stage disease while four treated cases have survived 15.7 
years, and two are alive. 
little is known regarding the natural history of AHD that it is 
difficult to speculate on what the eventual survival time will 
be among the treated patients. Nevertheless, since all have 
remained asymptomatic and, with the exception of the one 
noncompliant patient, no enlargement of the lesion has been 
discerned for a period averaging nearly 5 years, we believe 
that they, as a group, can be expected to survive well beyond 
the untreated patients. The 5-year survival rate was 56% for 
the untreated group and 90% for the treated groups. The 
10-year survival rate among untreated patients with a diag- 
nosis of AHD before 1981 was 3 1% (five of 16) and 75% (six 
of eight) in the treated groups. Ammann et al. [23] also re- 
ported improved survival among 60 patients treated with 
long-term mebendazole therapy. The 5-year survival rate for 
these patients was 96%, and at 10 years, 84%. For untreated 
historical controls the 10-year survival rate was <10%. 
Discussion 
The natural clinical course of untreated AHD has a wide 
spectrum of presentations. Some lesions appear to respond to 
host defenses and are spontaneously cured [6]. More charac- 
teristically, however, the course of untreated AHD is that of 
relentless growth with invasion of vital structures, resulting 
in obstruction of the inferior vena cava, major bile ducts, or 
portal blood flow; terminal anasarca often develops. A mas- 
sive liver or a greatly distended abdomen due to ascites char- 
acteristically develops. Before we conducted our first chemo- 
therapy trial in late 1974, 67% (16 of 24) of our cases 
developed along this dreadful course (three of the first four 
patients treated with mebendazole had marked hepatomeg- 
aly when treatment was initiated). In others, fatal brain me- 
tastases or extensive pulmonary metastases occurred. One 
may consider this progressive but lingering fatal course to be 
the "classic" clinical course of active, untreated AHD. 
The untreated AHD lesion consists of extremely dense 
fibrous tissue in which microcysts of the larval E. multilocu- 
laris are scattered [13]. The matrix is so dense that, as the 
lesion enlarges, blood vessels within the lesion are obliter- 
ated and a central zone of avascular necrosis characteristi- 
cally develops (figures 3 and 4). In such lesions, the volume 
of parasite tissue is low, and all but a minute fraction of such 
tissue consists of nonliving, laminated membranes. Because 
the nonliving membranes as well as the dense fibrous tissue 
associated with AHD lesions would not be affected by a par- 
asiticidal agent, reduction in lesion size, especially in the 
liver, may be minimal or may not occur at least during the 
first few years posttreatment. Where the larval E. multilocu- 
laris is rapidly proliferating and where less scar tissue de- 
velops, as in metastatic lesions, reduction in lesion size might 
be more likely to occur, as indeed was observed in each of 
two such patients (cases I and 2) who could be evaluated. 
Consequently, the arrest of growth of hepatic AHD lesions 
may well be all that is observed, even when the larval cestode 
is killed with therapy. Reduction in the size of the lesion 
should not necessarily be expected. 
Distant metastases appear to be associated largely with ad- 
vanced disease. Seven of the eight cases with metastases had 
advanced or end-stage disease when metastases were first ob- 
served. In Alaska, only two (20%) of the last 10 new active 
cases of AHD diagnosed since 1975 occurred in patients who 
presented with symptoms, compared to 78% before that time. 
It appears that improved diagnostic and surveillance tech- 
niques have led to the diagnosis of AHD when the lesion is 
smaller (5 cm vs. 13 cm) and at an earlier average age (43 
years vs. 59 years), thus permitting diagnosis and treatment 
before an advanced stage of disease has developed (which 
perhaps explains what appears to be a lower incidence of 
distant metastases in recent years). 
The clinical course of the first four patients to receive che- 
motherapy in 1974 was significantly altered. Two of these 
patients eventually died 14 and 17 years after the diagnosis 
of late complications of AHD was made, but their course did 
not follow the classic course described above. Two patients 
are living 15 and 22 years after diagnosis with what we be- 
lieve are dead lesions. These patients (nos. 2 and 5) have not 
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received chemotherapy for an average of 6.2 years. Their CT 
studies have shown no growth of the lesions for 10 years and 
there has been extensive or complete calcification of their 
primary lesions. In case 2, 27 of 30 pulmonary metastases are 
totally calcified; no growth has been observed in the re- 
mainder for 17 years [ 12]. In case 5, the EM2 ELISA serology 
was strongly positive from 1975 to 1986 and on each of 
seven tests has been consistently negative since 1986. Al- 
though serologies are often positive for patients with nonvi- 
able lesions because of retained laminated membranes, we 
believe the conversion to negative in this case is highly signifi- 
cant. These findings strongly suggest that the larval cestode 
is dead in each case. 
After an intense study of the first nine inactive cases diag- 
nosed [6], differentiation between an active AHD lesion and 
an inactive lesion in which the larval cestode has died has 
thus far not been difficult. Active lesions have been, without 
exception, of mixed density on CT [32]. They have been 
much larger in size and often were associated with symp- 
toms, end-stage disease, or metastasis, whereas none of the 
inactive lesions have presented in association with these fea- 
tures. Among 26 cases identified as dead or inactive, all have 
had very densely calcified lesions and no demonstrable hy- 
podense areas on CT. Of the lesions, 22 (85%) were <2 cm in 
diameter, only one (3.8%) was >3 cm in diameter [6], and 
none was associated with symptoms; no patients developed 
end-stage disease or metastases. There is no evidence to sug- 
gest that any of the 13 treated cases presented in table 2 had 
inactive disease at the time of diagnosis: the average lesion 
size was 9.8 cm (range, 3 cm-26 cm); the viability of the 
cestode was demonstrated by a positive viability assay with 
voles for six; three others had symptoms or end-stage disease; 
and viability was also evaluated in two cases by histopatho- 
logic examination of surgical tissue. The determination of 
viability was based on CT findings for only two of these pa- 
tients (cases 5 and 53), and each had a typical mixed-density 
lesion, 4 cm and 10 cm in diameter, respectively. The lesion 
in case 53, discussed below, was the only one for which viabil- 
ity of the cestode could be seriously questioned. Thus far we 
have seen little reason to consider a lesion with typical mixed 
densities on CT as anything other than active. As improved 
screening methods permit diagnosis of active cases when the 
lesion is quite small, this issue may become difficult and re- 
quire more study. 
Vole-inoculation studies. We believe the vole-inoculation 
test represents the best and the only direct means of assessing 
viability of larval E. multilocularis. It is the standard by 
which other viability methods are measured. In animal stud- 
ies Eckert [33] demonstrated extensive destruction with ne- 
crosis of larval E. multilocularis after administration of me- 
bendazole therapy. Yet inoculations into animals with use of 
tissue from these severely damaged and apparently necrotic 
vesicles resulted in regrowth of the larval cestode, a finding 
that demonstrated that residual, viable parasitic tissues were 
present. Schantz et al. reported that albendazole (as with 
mebendazole) was not parasiticidal against E. multilocularis 
in animal hosts even when the hosts were medicated continu- 
ously for up to five months [34]. The failure of mebendazole 
to kill the parasite in such in vivo studies in laboratory ani- 
mals is in part the basis for the widespread view that meben- 
dazole may be parasitistatic but not parasiticidal [15, 16, 35]. 
However, humans have a much more active immunologic 
response to E. multilocularis than do rodents, as evidenced 
by the absence of protoscolices together with the marked 
degree of necrosis and scarring associated with the lesion that 
develops in humans. The not-infrequent occurrence of spon- 
taneous cure with death of the larval cestode also indicates a 
good host defense in humans [6]. Thus, the combination of 
an active immunologic response and the effect of chemother- 
apy could result in death of the parasite in humans but not in 
rodents. 
The appearance of a typical E. multilocularis lesion on CT 
or an abdominal roentgenogram has been described as being 
of mixed density, with areas of calcification interspersed with 
radiolucent or hypodense areas [32, 36]. This finding sug- 
gests that these lesions continue to proliferate peripherally, 
with healing in deeper tissues, death of the larval cestode, 
and increasing calcification. The laminated membranes in 
the microcysts are durable. In autopsy specimens, as well as 
in old, calcified, inactive lesions [6], the membranes have 
been observed in abundance despite the fact that the results 
of all viability assays indicated that the parasite was dead. 
When membranes are collected for viability assay, the per- 
centage of microcysts that contain viable germinal tissue is 
not known but could be quite low. It is possible that among 
entire aliquots of membranes prepared for injection into 
voles there may be none with viable germinal cells. This 
may, in part, explain why proliferation fails to occur in some 
voles injected with membranes from viable lesions, as ob- 
served in cases 26, 30, 4, W, 5, and others (table 1), and is 
the reason why three voles are routinely injected. Prolifera- 
tion occurred in nine (60%) of 15 voles injected with tissues 
from untreated patients, while it occurred in only three (9%) 
of 34 voles injected with tissues from treated patients. 
The favorable results among Alaskan patients, as reflected 
by the results of viability tests with voles, were not achieved 
in an important investigation by Eckert and Jacquier (un- 
published). In vivo viability tests in gerbils were performed 
with use of tissue from 14 untreated Swiss patients. Positive 
results were obtained in I 1 (79%). Of tests on tissue from 12 
patients who had been treated from 1 to 108 months with 
mebendazole (1 1 patients) or albendazole (one patient), 10 
(83%) were positive. The difference in the numbers of posi- 
tive assays in the Swiss and Alaskan groups is striking but 
may be attributable largely to the duration of chemotherapy. 
The average period of treatment in Alaska was 70 months 
but was only 19 months in the Swiss experience. We seldom 
obtained negative test results unless the treatment had been 
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Table 4. Albendazole therapy: results of in vivo viability assays and clinical assessments among 
compliant patients. 
Serial CT examinations (X 5) 
Final 
Albendazole size of Results of 
Case therapy Initial lesion clinical 
no. (mo) Follow-up Vole test size (cm) Changes in CT image assessment 
39 2 6.6 - 4.3 ... * Excellent 
51 3.75 4.7 ND 3.4 X 4.5 3.5 X I Much-reduced hypodense Very good 
areas; calcifications 
more confluent and 
dense 
53 7 3.3 ND 2 X 4 1.5 X 3.2 Reduced hypodense areas; Very good 
calcifications more 
confluent and dense; 
decrease in size 
60 3 + 9 0.7 + 3.3 .. * Excellent 
(very weak) 
NOTE. CT = computed tomography; ND = not done. 
* Lesion surgically resected. 
given for >2 years. Only three patients in the Swiss study had 
been treated for this long, and the test was negative for one of 
them. 
The number of in vivo tests for which consistently nega- 
tive results were obtained for mebendazole-treated patients 
(table 1), together with supporting clinical observations, 
offers convincing evidence that long-term mebendazole ther- 
apy has been parasiticidal. The limited number of vole tests 
performed for albendazole-treated patients and the shorter 
time of follow-up make the interpretation of the results for 
this group more difficult. However, in assessing these results, 
the following considerations should be kept in mind. The 
objective of these chemotherapy trials was, and continues to 
be, to learn as much as we can as quickly as possible about 
the therapeutic dosage of albendazole. We were aware that 
while patients were receiving mebendazole therapy, the para- 
site had survived as long as 48 months and that albendazole 
was often hepatotoxic; thus it was important to determine 
the shortest duration of administration of the drug for effec- 
tive therapy. The first two vole tests gave negative results 
after only 2 and 3 months of therapy. More recent results 
indicate that the parasite, at least in case 60, survived 3 
months of treatment. The positive vole tests in cases 42 and 
60 should not be viewed so much as reflecting the failure of 
albendazole therapy but rather that the minimum treatment 
time should be >3 months. 
In view of the in vivo results together with the clinical 
observations on the four compliant patients who received 
albendazole, very impressive results were obtained that sug- 
gest that the long-term prognosis for these patients is excel- 
lent (table 4). In case 39 the negative vole test and negative 
postoperative serologies over 6.6 years are significant. The 
apparent reduced viability of the larval cestode with growth 
in only one of three injected voles in case 60 suggests that 3 
months of chemotherapy had severely injured the parasite. 
In cases 51 and 53, no posttreatment issue was available for 
in vivo studies. The clinical results, as reflected in the results 
of five serial CT studies, however, are very encouraging. In 
both cases, not only was there no growth of the lesion, but 
there has been a significant reduction in the amount of hypo- 
dense tissue; the calcifications have become more confluent 
and solid during the 3.3 and 4.7 years of observation. We are 
certain that in each case the lesion was active at the time 
chemotherapy was started because the pretreatment vole test 
in case 51 was positive and, in both cases, changes in the 
appearance on computed tomograms were observed over 
time. Had the lesion been dead, no change in appearance 
would have been expected. The advantages of a drug that is 
effective over months rather than years are so great that we 
feel continued emphasis on clinical trials with albendazole is 
justified. 
We have presented our experience with albendazole for 
the treatment of AHD as well as evidence that it may be 
hepatotoxic in some cases [27]. Certainly, the need for close 
monitoring of all patients who receive the drug must be 
clearly recognized. There continues to be an urgent need to 
learn as much as possible from each new case of AHD. Our 
experience with this disease has persuaded us that postpon- 
ing surgery adds little risk provided the patient is receiving 
appropriate chemotherapy. It is suggested that for all newly 
diagnosed cases, both of resectable and nonresectable lesions 
due to E. multilocularis, 4-6 months of preoperative therapy 
with albendazole be administered and be followed by viabil- 
ity studies on subsequent biopsy specimens or resected tis- 
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sues. A drug-free interval of 1 week before surgery is sug- 
gested so that residual drugs in the tissue do not give false in 
vivo assay results (this precaution was taken in case 60 but 
not in previous studies). Although the therapeutic serum 
level of albendazole is not known, the dose should be ad- 
justed to assure an albendazole sulfoxide serum level of 
-~ 1,000 ng/mL. Until therapeutic parameters are better de- 
fined, we feel that, following biopsy or resectional surgery, 
additional chemotherapeutic coverage with albendazole for 
a total of at least 12 months is advisable. 
Summary 
Most of these data suggest that the outcome of chemother- 
apy extends well beyond that of a favorable or parasitistatic 
effect. Some of the most convincing evidence for the success- 
ful killing of the larval E. multilocularis as a result of chemo- 
therapy includes the following findings. 
(1) Among 11 in vivo tests in six mebendazole-treated 
cases, the results of 10 consecutive tests performed since 
1978 have been negative (table 1). 
(2) In case 1 regression of the enlarging substernal metas- 
tasis from 26 mm to 8 mm (with negative results of a vole test 
on three occasions) occurred, with extended survival of the 
patient for 17 years. 
(3) The abrupt arrest of growth of numerous pulmonary 
metastases in case 2 was associated with this patient's sur- 
vival for 22 years, and recent CT studies showed complete 
calcification of 27 of 30 pulmonary metastases as well as of 
the primary hepatic lesion. 
(4) In case 4 the size of the hepatic abscess decreased 
without drainage, the surgical specimen appeared benign 
with loss of all matrix (figure 3), and the results of a vole test 
on the surgical tissue were negative. This patient is still living 
17 years after the diagnosis was made, and mebendazole ther- 
apy has been discontinued for 4.5 years without evidence of 
recurrence. 
(5) In case 5, followed for 15 years, a 7 X 10-cm hepatic 
lesion, initially proven to be active by the vole test, has dem- 
onstrated decreasing hypodense areas, increasing calcifica- 
tions, and no growth on serial CT studies over a 10-year 
period. The EM2 serologies, consistently strongly positive for 
10 years, have been negative on each of seven occasions 
since 1986 even though the patient has received no chemo- 
therapy for 6.7 years. 
(6) Among five patients treated with albendazole, vole 
viability assays were negative after 2 months of therapy for 
one patient; in two patients there was evidence of significant 
damage to the larval cestode after 1.5 and 3 months of ther- 
apy, respectively. For two other patients with resectable le- 
sions who were treated with only albendazole, serial CT stud- 
ies showed a decrease in the extent of radiolucent areas, an 
increase and confluence of calcifications, and no growth over 
4 years. Although more time is required to fully assess this 
group of patients, the findings are consistent with a lethal 
effect of albendazole therapy. 
(7) A comparative review of treated vs. untreated cases 
revealed striking differences. Among 21 untreated cases 
there was severe progression of disease in 95%, end-stage dis- 
ease developed in 81%, and all patients have died after an 
average survival time of only 5.3 years. Among 13 treated 
cases, excluding the noncompliant patient, none showed se- 
vere progression or developed end-stage disease; in 77% there 
was objective evidence of a favorable response to therapy, 
and survival time is now 13.6 years (eight patients are still 
living and asymptomatic). 
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